Clinical trial
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
NCT00347412 · Cellectar Biosciences, Inc., Industry · Completed
Key facts
| NCT number | NCT00347412 |
|---|---|
| Title | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer |
| Official title | Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) |
| Lead sponsor | Cellectar Biosciences, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, NOV-002, Carboplatin |
| Enrollment | 903 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jul 4, 2006 |
| Last update posted | Jul 25, 2022 |
| Countries | Canada, Israel, Italy, Poland, Romania, Russia, Serbia, Spain, Switzerland, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: